Unión Europea - español - EMA (European Medicines Agency)

immunomedics gmbh - sulesomab - osteomyelitis; radionuclide imaging - agentes de diagnóstico - este medicamento es solo para uso diagnóstico. leukoscan está indicado para el diagnóstico por imágenes para determinar la ubicación y extensión de la infección/inflamación en el hueso en pacientes con sospecha de osteomielitis, incluyendo a los pacientes con úlceras de pie diabético. leukoscan no ha sido empleada para diagnosticar la osteomielitis en pacientes con anemia de las células falciformes.

Unión Europea - español - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, pulmón no microcítico - agentes antineoplásicos - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Unión Europea - español - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agentes antineoplásicos - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

medac gesellschaft fÜr klinische spezialprÄparate gmbh - bcg cultivo vivo desecado - polvo para suspensiÓn intravesical - n/a - bcg cultivo vivo desecado n/a n/a - vacuna bcg

Unión Europea - español - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agentes antineoplásicos - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia está indicado para el tratamiento de pacientes adultos con localmente avanzado o metastásico de pulmón no microcítico después de la quimioterapia previa. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia está indicado para el tratamiento de pacientes adultos con localmente avanzado o metastásico de pulmón no microcítico después de la quimioterapia previa. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kowa pharmaceutical europe gmbh - pitavastatina - comprimido recubierto con pelÍcula - 2 mg - pitavastatina 2 mg - pitavastatina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kowa pharmaceutical europe gmbh - pitavastatina - comprimido recubierto con pelÍcula - 4 mg - pitavastatina 4 mg - pitavastatina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kowa pharmaceutical europe gmbh - pitavastatina - comprimido recubierto con pelÍcula - 1 mg - pitavastatina 1 mg - pitavastatina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kowa pharmaceutical europe gmbh - pitavastatina - comprimido recubierto con pelÍcula - 1 mg - pitavastatina 1 mg - pitavastatina